Senile osteoporosis: An update;Osteoporosis senil: Una actualización

Revista Espanola de Geriatria y Gerontologia

Volumn 46, Issue 4, 2011, Pages 223-229

  Alonso Bouzon, Cristina ^a,b   Duque, Gustavo ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Adipogenesis; Ageing; Osteoblastogenesis; Osteoporosis

Indexed keywords

ADIPOGENESIS; AGED; HUMAN; PATHOPHYSIOLOGY; SENILE OSTEOPOROSIS; SHORT SURVEY;

EID: 79960467872     PISSN: 0211139X     EISSN: 15781747     Source Type: Journal    
DOI: 10.1016/j.regg.2011.02.010     Document Type: Short Survey

References (91)

1. Raisz L.G., Rodan G.A. Pathogenesis of osteoporosis. Endocrinol Metab Clin North Am 2003, 32:15-24.
2. Lin J.T., Lane J.M. Rehabilitation of the older adult with an osteoporosis-related fracture. Clin Geriatr Med 2006, 22:435-447.
3. Brown L.B., Streeten E.A., Shapiro J.R., McBride D., Shuldiner A.R., Peyser P.A., et al. Genetic and environmental influences on bone mineral density in pre- and post-menopausal women. Osteoporos Int 2005, 16:1849-1856.
4. Tenenhouse A., Joseph L., Kreiger N., Poliquin S., Murray T.M., Blondeau L., et al. Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2000, 11:897-904.
5. Colon-Emeric C.S., Saag K.G. Osteoporotic fractures in older adults. Best Pract Res Clin Rheumatol 2006, 20:695-706.
6. Dempster D.W. Bone microarchitecture and strength. Osteoporos Int 2003, 14(Suppl 5):54-56.
7. Kim C.H., Takai E., Zhou H., von Stechow D., Müller R., Dempster D.W., et al. Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. J Bone Miner Res 2003, 18:2116-2125.
8. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005, 115:3318-3325.
9. Chan G.K., Duque G. Age-related bone loss: old bone, new facts. Gerontology 2002, 48:62-71.
10. Rauch F., Travers R., Glorieux F.H. Intracortical remodeling during human bone development--a histomorphometric study. Bone 2007, 40:274-280.
11. Troen B.R. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 2003, 38:605-614.
12. Troen B.R. The regulation of cathepsin K gene expression. Ann N Y Acad Sci 2006, 1068:165-172.
13. Ellies D.L., Krumlauf R. Bone formation: The nuclear matrix reloaded. Cell 2006, 125:840-842.
14. Roodman G.D. Regulation of osteoclast differentiation. Ann N Y Acad Sci 2006, 1068:100-109.
15. Yeung R.S. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss. J Rheumatol 2004, 31:844-846.
16. Mundy G.R., Elefteriou F. Boning up on ephrin signaling. Cell 2006, 126:441-443.
17. Weinstein R.S., Manolagas S.C. Apoptosis and osteoporosis. Am J Med 2000, 108:153-164.
18. Garn SM, Rohman CG, Nolan P. The developmental nature of bone changes during aging. In: Birren JE, ed. Relations of development and aging. Springfield: Charles C Thomas; 1966. p. 41-61.
19. Manolagas S.C., Kousteni S., Jilka R.L. Sex steroids and bone. Recent Prog Horm Res 2002, 57:385-409.
20. Lips P. Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol 2007, 103:620-625.
21. Kira M., Kobayashi T., Yoshikawa K. Vitamin D and the skin. J Dermatol 2003, 30:429-437.
22. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22:477-501.
23. Docheva D., Popov C., Mutschler W., Schieker M. Human mesenchymal stem cells in contact with their environment: surface characteristics and the integrin system. J Cell Mol Med 2007, 11:21-38.
24. Gimble J.M., Zvonic S., Floyd Z.E., Kassem M., Nuttall M.E. Playing with bone and fat. J Cell Biochem 2006, 98:251-266.
25. de Boer J., Andressoo J.O., de Wit J., Huijmans J., Beems R.B., van Steeg H., et al. Premature aging in mice deficient in DNA repair and transcription. Science 2002, 296:1276-1279.
26. Mitsui A., Hamuro J., Nakamura H., Kondo N., Hirabayashi Y., Ishizaki-Koizumi S., et al. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid Redox Signal 2002, 4:693-696.
27. Yudoh K., Nishioka K. Telomerized presenescent osteoblasts prevent bone mass loss in vivo. Gene Ther 2004, 11:909-915.
28. De Sandre-Giovannoli A., Bernard R., Cau P., Navarro C., Arriel J., Boccaccio I., et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003, 300:2055.
29. de Paula Rodrigues G.H., das Eiras Tamega I., Duque G., Spinola Dias Neto V. Severe bone changes in a case of Hutchinson-Gilford syndrome. Ann Genet 2002, 45:151-155.
30. Bergo M.O., Gavino B., Ross J., Schmidt W.K., Hong C., Kendall L.V., et al. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A 2002, 99:13049-13054.
31. Duque G., Rivas D. Age-related changes in lamin A/C expression in the osteoarticular system: laminopathies as a potential new aging mechanism. Mech Ageing Dev 2006, 127:378-383.
32. Pendas A.M., Zhou Z., Cadinanos J., Freije J.M., Wang J., Hultenby K., et al. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 2002, 31:94-99.
33. Rosen C.J., Bouxsein M.L. Mechanisms of disease: is osteoporosis the obesity of bone?. Nat Clin Pract Rheumatol 2006, 2:35-43.
34. Perrien D.S., Akel N.S., Dupont-Versteegden E.E., Skinner R.A., Siegel E.R., Suva L.J., et al. Aging alters the skeletal response to disise in the rat. Am J Physiol Regul Integr Comp Physiol 2007, 292:R988-996.
35. McCauley L.K., Tozum T.F., Kozloff K.M., Koh-Paige A.J., Chen C., Demashkieh M., et al. Transgenic models of metabolic bone disease: impact of estrogen receptor deficiency on skeletal metabolism. Connect Tissue Res 2003, 44(Suppl 1):250-263.
36. Duque G. As a matter of fat: new perspectives on the understanding of aged-related bone loss. BoneKEy osteovision 2007, 4:129-140.
37. Gasparrini M., Rivas D., Elbaz A., Duque G. Differential expression of cytokines in subcutaneous and marrow fat of aging C57BL/6J mice. Exp Gerontol 2009, 44:613-618.
38. Musacchio E., Priante G., Budakovic A., Baggio B. Effects of unsaturated free fatty acids on adhesion and on gene expression of extracellular matrix macromolecules in human osteoblast-like cell cultures. Connect Tissue Res 2007, 48:34-38.
39. Duque G. Will reducing adipogenesis in bone increase bone mass?: PPARgamma2 as a key target in the treatment of age-related bone loss. Drug News Perspect 2003, 16:341-346.
40. Schwartz A.V., Sellmeyer D.E., Vittinghoff E., Palermo L., Lecka-Czernik B., Feingold K.R., et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006, 91:3349-3354.
41. Hampton T. Diabetes drugs tied to fractures in women. JAMA 2007, 297:1645.
42. Botolin S., McCabe L.R. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol 2006, 209:967-976.
43. Ng A., Duque G. Osteoporosis as a lipotoxic disease. BoneKEy-Osteovision 2010, 7:108-123.
44. Moester M.J.C., Papapoulos S.E., Löwik C.W.G.M., van Bezooijen R.L. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010, 87:99-107.
45. Rubin J., Rubin C., Jacobs C.R. Molecular pathways mediating mechanical signaling in bone. Gene 2006, 367:1-16.
46. Szulc P., Beck T.J., Marchand F., Delmas P.D. Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men--the MINOS study. J Bone Miner Res 2005, 20:721-729.
47. de Kam D., Smulders E., Weerdesteyn V., Smits-Engelsman B.C. Exercise interventions to reduce fall-related fractures and their risk factors in individuals with low bone density: a systematic review of randomized controlled trials. Osteoporos Int 2009, 20:2111-2125.
48. Bailey C.A., Kukuljan S., Daly R.M. Effects of lifetime loading history on cortical bone density and its distribution in middle-aged and older men. Bone 2010, 47:673-680.
49. Nikander R., Sievänen H., Heinonen A., Daly R.M., Uusi-Rasi K., Kannus P. Targeted exercise against osteoporosis: A systematic review and meta-analysis for optimising bone strength throughout life. BMC Med 2010, 8:47.
50. Gusi N., Raimundo A., Leal A. Low-frequency vibratory exercise reduces the risk of bone fracture more than walking: a randomized controlled trial. BMC Musculoskel Dis 2006, 7:92.
51. Bolland M.J., Avenell A., Baron J.A., Grey A., McLennan G.S., Gamble G.D., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010, 341:c3691.
52. Tang B.M.P., Eslick G.D., Nowson C., Smith C., Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analyses. Lancet 2007, 370:657-666.
53. Cleland J.G., Witte K., Steel S. Calcium supplements in people with osteoporosis. BMJ 2010, 341:c3856.
54. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Stuck A.E., Staehelin H.B., Orav E.J., et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009, 169:551-556.
55. Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B., Orav E.J., Stuck A.E., Theiler R., et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomized controlled trials. BMJ 2009, 339:b3692.
56. Gloth F.M. Vitamin D. The Aging Skeleton 1999, Academic Press, San Diego, p. 185-91. C.J. Rosen, J. Glowacki, J.P. Bilezikian (Eds.).
57. Duque G., Macoritto M., Dion N., Ste-Marie L.G., Kremer R. 1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). Am J Physiol Endocrinol Metab 2005, 288:E723-E730.
58. Duque G., El Abdaimi K., Henderson J.E., Lomri A., Kremer R. Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways. Bone 2004, 35:57-64.
59. Duque G., Macoritto M., Kremer R. Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity. Biogerontology 2004, 5:421-429.
60. Zhang Y., Lai W.P., Wu C.F., Favus M.J., Leung P.C., Wong M.S. Ovariectomy worsens secondary hyperparathyroidism in mature rats during low-Ca diet. Am J Physiol Endocrinol Metab 2007, 292:E723-E731.
61. Mann V., Huber C., Kogianni G., Collins F., Noble B. The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007, 40:674-684.
62. Syed F.A., Oursler M.J., Hefferan T.E., Peterson J.M., Riggs B.L., Khosla S. Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. Osteoporos Int 2008, 19:1323-1330.
63. Burger H.G. Hormone therapy in the WHI era. Aust N Z J Obstet Gynaecol 2006, 46:84-91.
64. Adler R.A. Epidemiology and pathophysiology of osteoporosis in men. Curr Osteoporos Rep 2006, 4:110-115.
65. Leifke E., Korner H.C., Link T.M., Behre H.M., Peters P.E., Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. European journal of endocrinology /European Federation of Endocrine Societies 1998, 138:51-58.
66. Behre H.M., Kliesch S., Leifke E., Link T.M., Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997, 82:2386-2390.
67. Srinivas-Shankar U., Roberts S.A., Connolly M.J., O'Connell M.D.L., Adams J.E., Oldham J.A., et al. Effects of testosterone on muscle strength, physical function, body composition and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. JCEM 2010, 95:639-650.
68. Morley J.E. Should frailty be treated with testosterone?. Aging Male 2011, 14:1-3.
69. Mulder J.E., Kolatkar N.S., LeBoff M.S. Drug insight: Existing and emerging therapies for osteoporosis. Nat Clin Pract Endocrinol Metab 2006, 2:670-680.
70. Russell R.G. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006, 1068:367-401.
71. Duque G., Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 2007, 22:1603-1611.
72. Duque G., Vidal C., Rivas D. Protein isoprenylation regulates osteogenic differentiation of mesenchymal stem cells: effect of alendronate, and farnesyl and geranylgeranyl transferase inhibitors. Br J Pharmacol 2011, 162:1109-1118.
73. Duque G., Li W., Adams M., Xu S., Phipps R. Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporos Int 2011, 22:1547-1553.
74. Boonen S. Treatment of senile osteoporosis: present and future. Osteoporosis in Older Persons: Pathophysiology and Therapeutic Approach 2007, Springer, New York, p. 137-52. G. Duque, D.P. Kiel (Eds.).
75. Boonen S., Black D.M., Colon-Emeric C.S., Eastell R., Magaziner J.S., Eriksen E.F., et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010, 58:292-299.
76. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Abadri J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
77. Girgis C.M., Sher D., Seibel M.J. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010, 362:1848-1849.
78. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev. 2006:CD005326.
79. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459-468.
80. Reginster J.Y., Seeman E., de Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005, 90:2816-2822.
81. Seeman E., Vellas B., Benhamou C., Aquino J.P., Semler J., Kaufman J.M., et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006, 21:1113-1120.
82. Hamann K.L., Lane N.E. Parathyroid hormone update. Rheum Dis Clin North Am 2006, 32:703-719.
83. Chen P., Miller P.D., Delmas P.D., Misurski D.A., Krege J.H. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006, 21:1785-1790.
84. Boonen S., Marin F., Mellstrom D., Xie L., Desaiah D., Krege J.H., et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006, 54:782-789.
85. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl J Med 2009, 361:756-765.
86. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.
87. Bone H.G., McClung M.R., Roux C., Recker R.R., Eisman J.A., Verbruggen N., Hustad C.M., et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010, 25:937-947.
88. Li X., Ominski M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24:578-588.
89. Duque G., Huang D.C., Dion N., Macoritto M., Rivas D., Li W., et al. Interferon gamma plays a role in bone formation and rescues osteoporosis in ovariectomized mice. Bone Miner Res 2011, 10.1002/jbmr.350.
90. Backesjo C.M., Li Y., Lindgren U., Haldosén L.A. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 2006, 21:993-1002.
91. David V., Martin A., Lafage-Proust M.H., Peyroche S., Jones D.B., et al. Mechanical loading down-regulates peroxisome proliferator-activated receptor gamma in bone marrow stromal cells and favors osteoblastogenesis at the expense of adipogenesis. Endocrinology 2007, 148:2553-2562.